These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 43755)

  • 21. [Therapeutic measures in tardive dyskinesia].
    Tegeler J; Wöller W
    Fortschr Neurol Psychiatr; 1983 Jun; 51(6):203-26. PubMed ID: 6136457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sulpiride in tardive dyskinesia.
    Casey DE; Gerlach J; Simmelsgaard H
    Psychopharmacology (Berl); 1979; 66(1):73-7. PubMed ID: 44375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
    Glazer WM
    J Clin Psychiatry; 2000; 61 Suppl 4():21-6. PubMed ID: 10739327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine-receptor blockade and tardive dyskinesia.
    Bateman DN; Blain PG
    Lancet; 1979 Sep; 2(8143):641. PubMed ID: 90307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
    Correll CU; Leucht S; Kane JM
    Am J Psychiatry; 2004 Mar; 161(3):414-25. PubMed ID: 14992963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical neuroleptics: clozapine and the benzamides in the prevention and treatment of tardive dyskinesia.
    Pi EH; Simpson GM
    Mod Probl Pharmacopsychiatry; 1983; 21():80-6. PubMed ID: 6140635
    [No Abstract]   [Full Text] [Related]  

  • 28. Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs.
    Lévesque C; Hernandez G; Mahmoudi S; Calon F; Gasparini F; Gomez-Mancilla B; Blanchet PJ; Lévesque D
    Neuroscience; 2017 Oct; 361():43-57. PubMed ID: 28790021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.
    Quinn N; Marsden CD
    J Neurol Neurosurg Psychiatry; 1984 Aug; 47(8):844-7. PubMed ID: 6236286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of dopamine antagonists in spontaneous and tardive dyskinesia.
    Fog R
    Psychopharmacology Suppl; 1985; 2():118-21. PubMed ID: 2860655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tardive dyskinesia: a role for the endogenous opioid system.
    Sandyk R
    Med Hypotheses; 1986 Jan; 19(1):71-4. PubMed ID: 2871480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.
    Allen RM
    Biol Psychiatry; 1982 Jun; 17(6):719-27. PubMed ID: 6179548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of metoclopramide hydrochloride in patients with residual schizophrenia with tardive dyskinesias].
    Kiehl U; Nitzsche M; Fischer GJ
    Psychiatr Neurol Med Psychol (Leipz); 1985 Dec; 37(12):722-6. PubMed ID: 2869538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics.
    Chouinard G; Steinberg S
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):571-8. PubMed ID: 6131490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia.
    Lublin H; Gerlach J; Hagert U; Meidahl B; Mølbjerg C; Pedersen V; Rendtorff C; Tolvanen E
    Eur Neuropsychopharmacol; 1991 Dec; 1(4):541-8. PubMed ID: 1822319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review article: metoclopramide and tardive dyskinesia.
    Rao AS; Camilleri M
    Aliment Pharmacol Ther; 2010 Jan; 31(1):11-9. PubMed ID: 19886950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholinergic medication for neuroleptic-induced tardive dyskinesia.
    Tammenmaa IA; McGrath JJ; Sailas E; Soares-Weiser K
    Cochrane Database Syst Rev; 2002; (3):CD000207. PubMed ID: 12137608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.
    Ganzini L; Casey DE; Hoffman WF; McCall AL
    Arch Intern Med; 1993 Jun; 153(12):1469-75. PubMed ID: 8512437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
    Singh A; Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.